下肢动脉硬化闭塞症药物治疗及评价  

The pharmacotherapy and evaluation of lower extremity atherosclerotic occlusive diseases

作　　者：吴庆华[1] 

机构地区：[1]首都医科大学附属北京安贞医院血管外科,北京100029

出　　处：《中国实用外科杂志》2016年第12期1256-1259,共4页Chinese Journal of Practical Surgery

摘　　要：下肢动脉硬化闭塞症作为动脉硬化性血管病的一种疾病,其发病率呈明显上升趋势。高血压、血脂异常、糖尿病、吸烟等心血管病危险因素水平的持续上升是导致我国居民动脉硬化闭塞性疾病发病率上升的主要原因。故防治动脉硬化闭塞性疾病应以控制危险因素为切入点,药物治疗具有关键性作用。应重视临床研究以制定相关指南,以此给予病人规范化的药物治疗包括抗血小板、降脂、控制血糖和血压,以延缓动脉硬化进展,改善下肢缺血症状,确保术后支架或移植物通畅率,降低心脑血管事件的发生,最终提高病人的存活率。Lower extremity atherosclerotic occlusive diseases, as one of atherosclerotic occlusive diseases, the incidence of which has been significantly increased. The continuous rise of cardiovascular risk factors such as hypertension, dyslipidemia, diabetes mellitus, smoking and so on are the main causes of the prevalence of arteriosclerosis occlusive disease in China. Therefore, prevention and treatment of arteriosclerosis occlusive disease should be based on the control of risk factors. Pharmacotherapy has a key role. Surgeons should pay more attention to clinical research in order to formulate the guidelines, based on which patients could receive standardized drug treatment, including anti-platelet, lipid-lowering,regulating blood sugar and blood pressure.The purposes are to delay the progress of arteriosclerosis, to improve the ischemic symptoms of the lower limb, to ensure the stent or graft＇ s patency rate, to reduce the incidence of cardiovascular and cerebrovascular events, and ultimately to improve the survival rate of patients.

关 键 词：动脉硬化闭塞症 药物治疗 

分 类 号：R6[医药卫生—外科学]